Knowledge HQ

This study enhanced NK cell bone marrow homing by transfecting them with a CXCR4 variant. NK cells were expanded ex vivo for 14-18 days in G-Rex with feeder cells, providing a robust platform for generating cells for genetic modification.

This study established an automated process for Treg expansion on the CliniMACS Prodigy. Manual expansion in G-Rex 100 and G-Rex 10 served as the standard control, showing comparable expansion kinetics and phenotype to the automated system.

The authors developed a streamlined manufacturing process for CAR-T cells performed entirely within G-Rex. This approach, including transduction in the G-Rex, reduced costs and labor while maintaining cell quality compared to bag-based methods.

This study validates leukoreduction system chambers as a source of PBMCs for T cell therapy. G-Rex culture vessels were used to generate and expand pathogen-specific T cell lines, showing they are equivalent to those derived from peripheral blood.

The study investigates combining BRAF inhibitors with TIL therapy for resistant melanoma. In the associated clinical trial, patient TILs were rapidly expanded in G-Rex, facilitating the combination therapy approach.

This Phase 1 trial demonstrated the safety of NKG2D CAR-T cells in hematologic cancers. G-Rex were used for the ex vivo expansion of CAR-T cells during the 9-day manufacturing process, ensuring sufficient cell yield for infusion.

A method to expand Vγ9Vδ2 T cells using engineered K562 aAPCs was optimized in G-Rex vessels. The G-Rex platform enabled the generation of large numbers of functional gamma-delta T cells suitable for CAR modification and allogeneic therapy.

This study evaluated G-Rex culture systems for producing megakaryocytes from CD34+ cells. G-Rex cultures with optimized seeding densities significantly increased the expansion of Mk progenitors and overall yield compared to standard tissue culture surfaces.

This study identified neoepitopes recognized by TILs from glioblastoma patients. G-Rex were used to expand TILs from tumor digests in the presence of OKT3 and irradiated feeder cells, providing sufficient cells for immune reactivity testing.

This paper reports the creation of anti-CD3 CAR-T cells (3CAR) using TALEN-mediated TCR disruption to avoid self-killing. G-Rex were used to scale up the production, allowing 3CAR T cells to expand 100-fold and self-enrich for the TCR-negative population.

A novel TIL expansion method combining IL-2, anti-4-1BB, and OKT3 was developed. Using small G-Rex 10 devices allowed for successful expansion from fewer tumor fragments and reduced culture time compared to standard methods, especially for uveal melanoma.

A 9-day manufacturing process for NKG2D CAR-T cells was developed for a Phase I trial. G-Rex 100 were utilized for the ex vivo expansion step, enabling the production of therapeutic doses of viable and functional CAR-T cells from patient material.